Why is Liquid Biopsy So Important? Part 1 with Dennis Merkle, CEO of Predicine Europe.

Adam Hargreaves By Adam Hargreaves

In the second episode of Diagnostics Digest, I chat to Dennis Merkle, CEO of Europe and Global Head of Biopharma Business at innovative molecular insights company, Predicine.

Dennis brings insight from his broad and brilliant background in molecular oncology and precision medicine, with experience in all elements from research to pharma and commercial. Here we jump into a well-rounded discussion on the benefits of liquid biopsy in today's oncology market.

This conversation comes in three parts. In part two, we delve into crucial barriers within the market. Part three discusses new liquid biopsy technologies and what's new at Predicine. Be sure to subscribe to be notified when all parts are available.

If you'd like to get in touch about this episode, be a future podcast guest, or learn more about CM Life Science's services, please email me at adam.hargeaves@lifesci-cm.com.

Recommended.